# Gene expression profiling of the human natural killer cell response to Fc receptor activation: unique enhancement in the presence of interleukin-12

**Authors:** Amanda R. Campbell, Kelly Regan, Neela Bhave, Arka Pattanayak, Robin Parihar, Andrew R. Stiff, Prashant Trikha, Steven D. Scoville, Sandya Liyanarachchi, Sri Vidya Kondadasula, Omkar Lele, Ramana Davuluri, Philip R. O. Payne, William E. Carson

PMC · DOI: 10.1186/s12920-015-0142-9 · 2015-10-15

## TL;DR

This study explores how natural killer cells respond to activation signals and finds that interleukin-12 enhances their gene expression, potentially improving their ability to fight cancer.

## Contribution

The study identifies a unique gene expression profile in NK cells when activated by Fc receptors and interleukin-12.

## Key findings

- Co-stimulation with FcR and IL-12 leads to a unique gene expression pattern in NK cells.
- Key genes like BATF, IRF4, TBX21, and IFNG are identified as important in the activated NK cell network.
- The findings suggest potential targets for enhancing anti-tumor activity of NK cells.

## Abstract

Traditionally, the CD56dimCD16+ subset of Natural Killer (NK) cells has been thought to mediate cellular cytotoxicity with modest cytokine secretion capacity. However, studies have suggested that this subset may exert a more diverse array of immunological functions. There exists a lack of well-developed functional models to describe the behavior of activated NK cells, and the interactions between signaling pathways that facilitate effector functions are not well understood. In the present study, a combination of genome-wide microarray analyses and systems-level bioinformatics approaches were utilized to elucidate the transcriptional landscape of NK cells activated via interactions with antibody-coated targets in the presence of interleukin-12 (IL-12).

We conducted differential gene expression analysis of CD56dimCD16+ NK cells following FcR stimulation in the presence or absence of IL-12. Next, we functionally characterized gene sets according to patterns of gene expression and validated representative genes using RT-PCR. IPA was utilized for biological pathway analysis, and an enriched network of interacting genes was generated using GeneMANIA. Furthermore, PAJEK and the HITS algorithm were employed to identify important genes in the network according to betweeness centrality, hub, and authority node metrics.

Analyses revealed that CD56dimCD16+ NK cells co-stimulated via the Fc receptor (FcR) and IL-12R led to the expression of a unique set of genes, including genes encoding cytotoxicity receptors, apoptotic proteins, intracellular signaling molecules, and cytokines that may mediate enhanced cytotoxicity and interactions with other immune cells within inflammatory tissues. Network analyses identified a novel set of connected key players, BATF, IRF4, TBX21, and IFNG, within an integrated network composed of differentially expressed genes in NK cells stimulated by various conditions (immobilized IgG, IL-12, or the combination of IgG and IL-12).

These results are the first to address the global mechanisms by which NK cells mediate their biological functions when encountering antibody-coated targets within inflammatory sites. Moreover, this study has identified a set of high-priority targets for subsequent investigation into strategies to combat cancer by enhancing the anti-tumor activity of CD56dimCD16+ NK cells.

The online version of this article (doi:10.1186/s12920-015-0142-9) contains supplementary material, which is available to authorized users.

## Linked entities

- **Genes:** BATF (basic leucine zipper ATF-like transcription factor) [NCBI Gene 10538], IRF4 (interferon regulatory factor 4) [NCBI Gene 3662], TBX21 (T-box transcription factor 21) [NCBI Gene 30009], IFNG (interferon gamma) [NCBI Gene 3458]

## Full-text entities

- **Genes:** IL12B (interleukin 12B) [NCBI Gene 3593] {aka CLMF, CLMF2, IL-12B, IMD28, IMD29, NKSF}, SLC7A5 (solute carrier family 7 member 5) [NCBI Gene 8140] {aka 4F2LC, CD98, D16S469E, E16, LAT1, MPE16}, BNIP3L (BCL2 interacting protein 3 like) [NCBI Gene 665] {aka BNIP3a, NIP3L, NIX}, IL21 (interleukin 21) [NCBI Gene 59067] {aka CVID11, IL-21, Za11}, FASLG (Fas ligand) [NCBI Gene 356] {aka ALPS1B, APT1LG1, APTL, CD178, CD95-L, CD95L}, ADRB2 (adrenoceptor beta 2) [NCBI Gene 154] {aka ADRB2R, ADRBR, ARB2, B2AR, BAR, BETA2AR}, MXI1 (MAX interactor 1, dimerization protein) [NCBI Gene 4601] {aka MAD2, MXD2, MXI, bHLHc11}, PTGDR (prostaglandin D2 receptor) [NCBI Gene 5729] {aka AS1, ASRT1, DP, DP1, PTGDR1}, STK17A (serine/threonine kinase 17a) [NCBI Gene 9263] {aka DRAK1}, TRAF1 (TNF receptor associated factor 1) [NCBI Gene 7185] {aka EBI6, MGC:10353}, NR4A2 (nuclear receptor subfamily 4 group A member 2) [NCBI Gene 4929] {aka HZF-3, IDLDP, NOT, NURR1, RNR1, TINUR}, BATF (basic leucine zipper ATF-like transcription factor) [NCBI Gene 10538] {aka B-ATF, BATF1, SFA-2, SFA2}, NLRP1 (NLR family pyrin domain containing 1) [NCBI Gene 22861] {aka AIADK, CARD7, CIDED, CLR17.1, DEFCAP, DEFCAP-L/S}, TRIB1 (tribbles pseudokinase 1) [NCBI Gene 10221] {aka C8FW, GIG-2, GIG2, SKIP1, TRB-1, TRB1}, IL3 (interleukin 3) [NCBI Gene 3562] {aka IL-3, MCGF, MULTI-CSF}, FGR (FGR proto-oncogene, Src family tyrosine kinase) [NCBI Gene 2268] {aka SRC2, c-fgr, c-src2, p55-Fgr, p55c-fgr, p58-Fgr}, P2RY10 (P2Y receptor family member 10) [NCBI Gene 27334] {aka LPS2, LYPSR2, P2Y10}, NOP14 (NOP14 nucleolar protein) [NCBI Gene 8602] {aka C4orf9, NOL14, RES4-25, RES425, UTP2}, CD38 (CD38 molecule) [NCBI Gene 952] {aka ADPRC 1, ADPRC1, cADPR1}, HLA-C (major histocompatibility complex, class I, C) [NCBI Gene 3107] {aka D6S204, HLA-JY3, HLAC, HLC-C, MHC, PSORS1}, CD300A (CD300a molecule) [NCBI Gene 11314] {aka CLM-8, CMRF-35-H9, CMRF-35H, CMRF35-H, CMRF35-H9, CMRF35H}, TBX21 (T-box transcription factor 21) [NCBI Gene 30009] {aka IMD88, T-PET, T-bet, TBET, TBLYM}, FCGR2A (Fc gamma receptor IIa) [NCBI Gene 2212] {aka CD32, CD32A, CDw32, FCG2, FCGR2, FCGR2A1}, ERBB2 (erb-b2 receptor tyrosine kinase 2) [NCBI Gene 2064] {aka CD340, HER-2, HER-2/neu, HER2, MLN 19, MLN-19}, CCND2 (cyclin D2) [NCBI Gene 894] {aka KIAK0002, MPPH3}, AHR (aryl hydrocarbon receptor) [NCBI Gene 196] {aka FVH3, RP85, bHLHe76}, BCL2A1 (BCL2 related protein A1) [NCBI Gene 597] {aka ACC-1, ACC-2, ACC1, ACC2, BCL2L5, BFL1}, KLF2 (KLF transcription factor 2) [NCBI Gene 10365] {aka LKLF}, IL15 (interleukin 15) [NCBI Gene 3600] {aka IL-15}, TNFRSF1B (TNF receptor superfamily member 1B) [NCBI Gene 7133] {aka CD120b, TBPII, TNF-R-II, TNF-R75, TNFBR, TNFR1B}, POTEF (POTE ankyrin domain family member F) [NCBI Gene 728378] {aka A26C1B, POTE2alpha, POTEACTIN}, CXCL9 (C-X-C motif chemokine ligand 9) [NCBI Gene 4283] {aka CMK, Humig, MIG, SCYB9, crg-10}, P2RX5 (purinergic receptor P2X 5) [NCBI Gene 5026] {aka LRH-1, P2X5, P2X5R}, CFLAR (CASP8 and FADD like apoptosis regulator) [NCBI Gene 8837] {aka CASH, CASP8AP1, CLARP, Casper, FLAME, FLAME-1}, TNFRSF9 (TNF receptor superfamily member 9) [NCBI Gene 3604] {aka 4-1BB, CD137, CDw137, ILA, IMD109}, NCAM1 (neural cell adhesion molecule 1) [NCBI Gene 4684] {aka CD56, MSK39, NCAM}, PLCG2 (phospholipase C gamma 2) [NCBI Gene 5336] {aka APLAID, FCAS3, PLC-IV, PLC-gamma-2}, CIDEB (cell death inducing DFFA like effector b) [NCBI Gene 27141], Fcr (Fc receptor) [NCBI Gene 109615], CCL1 (C-C motif chemokine ligand 1) [NCBI Gene 6346] {aka I-309, P500, SCYA1, SISe, TCA3}, FAS (Fas cell surface death receptor) [NCBI Gene 355] {aka ALPS1A, APO-1, APT1, CD95, FAS1, FASTM}, JAG1 (jagged canonical Notch ligand 1) [NCBI Gene 182] {aka AGS, AGS1, AHD, AWS, CD339, CMT2HH}, CCL3 (C-C motif chemokine ligand 3) [NCBI Gene 6348] {aka G0S19-1, LD78, LD78ALPHA, MIP-1-alpha, MIP1A, SCI}, CYCS (cytochrome c, somatic) [NCBI Gene 54205] {aka CYC, HCS, THC4}, COLQ (collagen like tail subunit of asymmetric acetylcholinesterase) [NCBI Gene 8292] {aka CMS5, EAD}, GTPBP4 (GTP binding protein 4) [NCBI Gene 23560] {aka CRFG, NGB, NOG1}, RIEG2 (Rieger syndrome 2) [NCBI Gene 6012] {aka ARS, RGS2}, ITGAL (integrin subunit alpha L) [NCBI Gene 3683] {aka CD11A, EV6, HNA-5, LFA-1, LFA1A}, SEPTIN6 (septin 6) [NCBI Gene 23157] {aka SEP2, SEPT2, SEPT6, Septin-6}, TNF (tumor necrosis factor) [NCBI Gene 7124] {aka DIF, IMD127, TNF-alpha, TNFA, TNFSF2, TNLG1F}, MTHFD2 (methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 2, methenyltetrahydrofolate cyclohydrolase) [NCBI Gene 10797] {aka NMDMC}, FCGR3B (Fc gamma receptor IIIb) [NCBI Gene 2215] {aka CD16, CD16-I, CD16b, FCG3, FCGR3, FCRIIIb}, CCNG2 (cyclin G2) [NCBI Gene 901], BATF3 (basic leucine zipper ATF-like transcription factor 3) [NCBI Gene 55509] {aka JDP1, JUNDM1, SNFT}, EIF5A (eukaryotic translation initiation factor 5A) [NCBI Gene 1984] {aka EIF-5A, EIF5A1, FABAS, eIF-4D, eIF5AI}, PTPRCAP (protein tyrosine phosphatase receptor type C associated protein) [NCBI Gene 5790] {aka CD45-AP, LPAP}, SPTBN1 (spectrin beta, non-erythrocytic 1) [NCBI Gene 6711] {aka DDISBA, ELF, HEL102, SPTB2, betaSpII}, ZFP36L2 (ZFP36 like 2 zinc finger CCCH-type) [NCBI Gene 678] {aka BRF2, ERF-2, ERF2, OOMD13, OZEMA13, RNF162C}, IARS1 (isoleucyl-tRNA synthetase 1) [NCBI Gene 3376] {aka GRIDHH, IARS, ILERS, ILRS, IRS, PRO0785}, IRF4 (interferon regulatory factor 4) [NCBI Gene 3662] {aka IMD131, LSIRF, MUM1, NF-EM5, SHEP8}
- **Diseases:** Connective Tissue Disorders (MESH:D003240), urothelial and renal cell carcinoma (MESH:D002292), Inflammatory Disease (MESH:D007249), NK (MESH:D000077428), breast cancer (MESH:D001943), Immunological Disease (MESH:D007154), cancer (MESH:D009369), autoimmune encephalomyelitis (MESH:D004681), BC (MESH:D008796), multiple sclerosis (MESH:D009103)
- **Species:** Plasmodium falciparum (malaria parasite P. falciparum, species) [taxon 5833], Plasmodium falciparum 3D7 (isolate) [taxon 36329], Homo sapiens (human, species) [taxon 9606], Mus musculus (house mouse, species) [taxon 10090]
- **Cell lines:** SK-BR-3 — Homo sapiens (Human), Breast adenocarcinoma, Cancer cell line (CVCL_0033)

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC4608307/full.md

---
Source: https://tomesphere.com/paper/PMC4608307